Evidence map›Paper›PMID 34967083›Full record

Observational studyEuropean journal of neurology2022

Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis.

Stephanie R Shepheard, Vassilios Karnaros, Beben Benyamin, David W Schultz, Megan Dubowsky, Joanne Wuu, Tim Chataway, Andrea Malaspina, Michael Benatar, Mary-Louise Rogers

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Stephanie R ShepheardFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.ORCID 0000-0002-2358-7348
Vassilios KarnarosFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Beben BenyaminAustralian Centre for Precision Health and Allied Health and Human Performance Unit, University of South Australia, Adelaide, South Australia, Australia.ORCID 0000-0001-5608-2293
David W SchultzNeurology Department and MND Clinic, Flinders Medical Centre, Adelaide, South Australia, Australia.ORCID 0000-0001-6319-7574
Megan DubowskyFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.ORCID 0000-0002-0146-4814
Joanne WuuDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Tim ChatawayFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.ORCID 0000-0003-0254-8099
Andrea MalaspinaNeuromuscular Department, Motor Neuron Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Michael BenatarDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Mary-Louise RogersFlinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.ORCID 0000-0002-3482-8741
Flinders University · AUUniversity of Miami · USFlinders Medical Centre · AUNational Hospital for Neurology and Neurosurgery · GBUniversity of South Australia · AU

Funding

Uncovering new genes and disease modifiers for ALS and related disordersU54NS092091 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LINDSAY N ALFANO · 2014 to 2026
$19.8M
Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)U01NS107027 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BENATAR, MICHAEL, MALASPINA, ANDREA · 2018 to 2023
$3.5M
Motor Neurone Disease Association MALASPINA/APR13/817-791Motor Neurone Disease Association TURNER/OCT15/972-797NINDS NIH HHS U01 NS107027NINDS NIH HHS U54 NS092091Wellcome Trust
6 · The paper itself

Abstract

background and purposeThe aim was to evaluate urinary neopterin, a marker of pro-inflammatory state, as a potential biomarker of disease prognosis and progression in amyotrophic lateral sclerosis (ALS); and to compare its utility to urinary neurotrophin receptor p75 extracellular domain (p75

methodsThis was an observational study including 21 healthy controls and 46 people with ALS, 29 of whom were sampled longitudinally. Neopterin and p75

resultsAt baseline, urinary neopterin was higher in ALS compared to controls (181.7 ± 78.9 μmol/mol creatinine vs. 120.4 ± 60.8 μmol/mol creatinine, p = 0.002, Welch's t test) and correlated with the Revised ALS Functional Rating Scale (r = -0.36, p = 0.01). Combining previously published urinary p75

conclusionUrinary neopterin holds promise as marker of disease progression in ALS and is worthy of future evaluation for its potential to predict response to anti-inflammatory therapies.

Indexed as

Amyotrophic Lateral SclerosisBiomarkersDisease ProgressionHumansNeopterinPrognosisBiomarkersNeopterinALSbiomarkerdisease progressionpharmacodynamicproinflammatory

Identifiers

PMID34967083
PMCPMC8901536
OpenAlexW4200387300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.